TABLE OF CONTENTS
Volume 19, Issue 6 (June 2005)
Spotlights on Angiogenesis |
Keynote Address |
Commentary |
Original Manuscripts |
Correspondence |
Corrigendum
Editorial
Allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia in first complete remission: new answers for an old question
A Shimoni and A Nagler
Leukemia 19: 891-893; doi:10.1038/sj.leu.2403771
Spotlights on Angiogenesis
Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications
P Korkolopoulou, I Thymara, N Kavantzas, T P Vassilakopoulos, M K Angelopoulou, S I Kokoris, E M Dimitriadou, M P Siakantaris, K Anargyrou, P Panayiotidis, A Tsenga, A Androulaki, I A Doussis-Anagnostopoulou, E Patsouris and G A Pangalis
Leukemia 19: 894-900; advance online publication, March 31, 2005; doi:10.1038/sj.leu.2403690
Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis
T Sanda, T Kuwano, S Nakao, S Iida, T Ishida, H Komatsu, K Shudo, M Kuwano, M Ono and R Ueda
Leukemia 19: 901-909; advance online publication, April 21, 2005; doi:10.1038/sj.leu.2403754
Keynote Address
Five decades of therapy for multiple myeloma: a paradigm for therapeutic models
R A Kyle
Leukemia 19: 910-912; advance online publication, March 31, 2005; doi:10.1038/sj.leu.2403728
Commentary
Therapeutic research in untreated acute promyelocytic leukemia
E Estey
Leukemia 19: 913-915; advance online publication, April 21, 2005; doi:10.1038/sj.leu.2403767
Original Manuscripts
Leading Article
The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison
M Mohty, H de Lavallade, P Ladaique, C Faucher, N Vey, D Coso, A-M Stoppa, J-A Gastaut and D Blaise
Leukemia 19: 916-920; advance online publication, April 21, 2005; doi:10.1038/sj.leu.2403770
Molecular Targets for Therapy
CBF
-SMMHC slows proliferation of primary murine and human myeloid progenitors
J D'Costa, S Chaudhuri, C I Civin and A D Friedman
Leukemia 19: 921-929; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403755
Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase
Y Komeno, M Kurokawa, Y Imai, M Takeshita, T Matsumura, K Kubo, T Yoshino, U Nishiyama, T Kuwaki, K Kubo, T Osawa, S Ogawa, S Chiba, A Miwa and H Hirai
Leukemia 19: 930-935; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403736
STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis
U Holtick, M Vockerodt, D Pinkert, N Schoof, B Stürzenhofecker, N Kussebi, K Lauber, S Wesselborg, D Löffler, F Horn, L Trümper and D Kube
Leukemia 19: 936-944; advance online publication, April 28, 2005; doi:10.1038/sj.leu.2403750
Therapy
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma
G W van Imhoff, B van der Holt, M A MacKenzie, G J Ossenkoppele, P W Wijermans, M H H Kramer, M B van 't Veer, H C Schouten, M van Marwijk Kooy, M H J van Oers, J M M Raemaekers, P Sonneveld, L A M H Meulendijks, P M Kluin, H C Kluin-Nelemans and L F Verdonck
Leukemia 19: 945-952; advance online publication, March 31, 2005; doi:10.1038/sj.leu.2403733
Acute Leukemias
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes
A Kohlmann, C Schoch, M Dugas, S Schnittger, W Hiddemann, W Kern and T Haferlach
Leukemia 19: 953-964; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403746
Acute Non-Lymphocytic Leukemias
Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era
T A Alonzo, R J Wells, W G Woods, B Lange, R B Gerbing, A B Buxton, S Neudorf, J Sanders, F O Smith and S A Feig
Leukemia 19: 965-970; advance online publication, April 14, 2005; doi:10.1038/sj.leu.2403763
Myelodysplasias
Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia
A Yoshimi, P Bader, S Matthes-Martin, J Starý, P Sedlacek, U Duffner, T Klingebiel, D Dilloo, W Holter, F Zintl, B Kremens, K-W Sykora, C Urban, H Hasle, E Korthof, T Révész, A Fischer, P Nöllke, F Locatelli and C M Niemeyer on behalf of European Working Group of MDS in Childhood (EWOG-MDS)
Leukemia 19: 971-977; advance online publication, March 31, 2005; doi:10.1038/sj.leu.2403721
Acute Promyelocytic Leukemia
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia
R F Schlenk, U Germing, F Hartmann, A Glasmacher, J T Fischer, F del Valle y Fuentes, K Götze, H Pralle, C Nerl, H Salwender, W Grimminger, A Petzer, M Hensel, A Benner, L Zick, K Döhner, S Fröhling and H Döhner for the AML Study Group (AMLSG)
Leukemia 19: 978-983; advance online publication, April 21, 2005; doi:10.1038/sj.leu.2403766
Chronic Myeloid Leukemia, BCR/ABL Studies and Myelo-Proliferative Syndromes
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
U Berger, O Maywald, M Pfirrmann, T Lahaye, A Hochhaus, A Reiter, J Hasford, H Heimpel, D K Hossfeld, H-J Kolb, H Löffler, H Pralle, W Queisser, R Hehlmann and and the German CML-Study Group
Leukemia 19: 984-989; advance online publication, April 14, 2005; doi:10.1038/sj.leu.2403756
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML
F R Kerbauy, R Storb, U Hegenbart, T Gooley, J Shizuru, H K Al-Ali, J P Radich, D G Maloney, E Agura, B Bruno, E M Epner, T R Chauncey, K G Blume, D Niederwieser and B M Sandmaier
Leukemia 19: 990-997; advance online publication, March 31, 2005; doi:10.1038/sj.leu.2403730
Identification of genes potentially involved in disease transformation of CML
J J W M Janssen, S M Klaver, Q Waisfisz, G Pasterkamp, D P V de Kleijn, G J Schuurhuis and G J Ossenkoppele
Leukemia 19: 998-1004; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403735
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1
C Walz, A Chase, C Schoch, A Weisser, F Schlegel, A Hochhaus, R Fuchs, A Schmitt-Gräff, R Hehlmann, N C P Cross and A Reiter
Leukemia 19: 1005-1009; advance online publication, March 31, 2005; doi:10.1038/sj.leu.2403712
Acute Lymphoblastic Leukemia
Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia
T Yamaguchi, Y Maeda, S Ueda, Y Hijikata, Y Morita, J-i Miyatake, M Matsuda and A Kanamaru
Leukemia 19: 1010-1017; advance online publication, April 21, 2005; doi:10.1038/sj.leu.2403760
Chronic Lymphocytic Leukemia and Normal B-Cells
ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype
J C Nolz, R C Tschumper, B T Pittner, J R Darce, N E Kay and D F Jelinek
Leukemia 19: 1018-1024; advance online publication, March 31, 2005; doi:10.1038/sj.leu.2403726
Chronic Lymphocytic Leukemia and Normal B-cells
CLL family 'Pedigree 14' revisited: 1947–2004
V Jønsson, R S Houlston, D Catovsky, M R Yuille, J Hilden, J H Olsen, M Fajber, B Brandt, G Sellick, R Allinson and A Wiik
Leukemia 19: 1025-1028; advance online publication, March 31, 2005; doi:10.1038/sj.leu.2403727
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis
P Dreger, R Brand, D Milligan, P Corradini, J Finke, G Lambertenghi Deliliers, R Martino, N Russell, A van Biezen, M Michallet and D Niederwieser on behalf of the Chronic Leukemia Working Party of the EBMT
Leukemia 19: 1029-1033; advance online publication, April 14, 2005; doi:10.1038/sj.leu.2403745
Apoptosis
Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli
M S Holtz, S J Forman and R Bhatia
Leukemia 19: 1034-1041; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403724
Gene Expression Profiling and Microarrays
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations
A Andersson, P Edén, D Lindgren, J Nilsson, C Lassen, J Heldrup, M Fontes, Å Borg, F Mitelman, B Johansson, M Höglund and T Fioretos
Leukemia 19: 1042-1050; advance online publication, April 21, 2005; doi:10.1038/sj.leu.2403749
Cell Cycle
G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression
M J Ausserlechner, P Obexer, S Geley and R Kofler
Leukemia 19: 1051-1057; advance online publication, March 31, 2005; doi:10.1038/sj.leu.2403729
Lymphoma
Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances
Y Guo, K Karube, R Kawano, T Yamaguchi, J Suzumiya, G-S Huang and K Ohshima
Leukemia 19: 1058-1063; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403738
Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody
R M Sharkey, H Karacay, C-H Chang, W J McBride, I D Horak and D M Goldenberg
Leukemia 19: 1064-1069; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403751
Genetic heterogeneity of the hypervariable region I of Hepatitis C virus and lymphoproliferative disorders
A Rigolet, P Cacoub, A Schnuriger, L Vallat, A Cahour, P Ghillani, F Davi, Y Benhamou, J-C Piette and V Thibault
Leukemia 19: 1070-1076; advance online publication, April 21, 2005; doi:10.1038/sj.leu.2403731
Correspondence
Thrombocytopenia after gemtuzumab is reversible by intravenous immunoglobulin
A Y H Leung and R Liang
Leukemia 19: 1077-1078; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403757
t(11;14) does not predict long-term survival in myeloma
H Chang, X Y Qi and A K Stewart
Leukemia 19: 1078-1079; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403744
Apoptosis-resistant phenotype of classical Hodgkin's lymphoma is not mediated by somatic mutations within genes encoding members of the death-inducing signaling complex (DISC)
R K Thomas, R Schmitz, A C Harttrampf, A Abdil-Hadi, C Wickenhauser, V Distler, M-L Hansmann, J L Schultze, R Küppers and J Wolf
Leukemia 19: 1079-1082; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403747
Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays
C Mestre, F Rubio-Moscardo, A Rosenwald, J Climent, M J S Dyer, L Staudt, D Pinkel, R Siebert and J A Martinez-Climent
Leukemia 19: 1082-1084; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403741
Identification of an HLA-A1 restricted CTL epitope from Mcl-1
M H Andersen, P Kvistborg, J C Becker and P thor Straten
Leukemia 19: 1084-1085; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403743
Can application of serine protease inhibitors TPCK and TLCK provide evidence for possible involvement of serine protease Omi/HtrA2 in imatinib mesylate-induced cell death of BCR-ABL-positive human leukemia cells?
P Mlejnek
Leukemia 19: 1085-1087; advance online publication, March 31, 2005; doi:10.1038/sj.leu.2403701
Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes
J M Hernández, C Castilla, N C Gutiérrez, I M Isidro, M Delgado, J de las Rivas, E Fermiñán, J L García, E M Ocio, M C del Cañizo and J F San Miguel
Leukemia 19: 1088-1091; advance online publication, April 14, 2005; doi:10.1038/sj.leu.2403753
Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy
E Mejst
íková, T Kalina, J Trka, J Starý and O Hru
ák
Leukemia 19: 1092-1094; advance online publication, April 14, 2005; doi:10.1038/sj.leu.2403737
Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: response to imatinib and reduced-intensity allogeneic stem cell transplant
S E Martin and J DellaValla
Leukemia 19: 1095-1096; advance online publication, March 24, 2005; doi:10.1038/sj.leu.2403725
Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript
S Meyer-Monard, D Mühlematter, A Streit, A J Chase, A Gratwohl, N C P Cross, M Jotterand and A Tichelli
Leukemia 19: 1096-1099; advance online publication, March 24, 2005; doi:10.1038/sj.leu.2403697
CD40 activation of B-CLL cells is associated with augmented intracellular levels of CD79b and increased BCR expression in a subset of patients
S Minuzzo, S Indraccolo, V Tosello, E Piovan, A Cabrelle, L Trentin, G Semenzato and A Amadori
Leukemia 19: 1099-1101; advance online publication, April 14, 2005; doi:10.1038/sj.leu.2403772
High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation
C Shimazaki, R Uchida, S Nakano, K Namura, S-i Fuchida, A Okano, M Okamoto and T Inaba
Leukemia 19: 1102-1103; advance online publication, April 14, 2005; doi:10.1038/sj.leu.2403758
Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4
K U Chow, D Nowak, W Hofmann, B Schneider and W-K Hofmann
Leukemia 19: 1103-1105; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403739
Reply to 'Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4' by Chow et al
R Aloyz and L Panasci
Leukemia 19: 1105-1106; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403740
Reply to Aloyz et al
K U Chow, D Nowak, W Hofmann, B Schneider and W-K Hofmann
Leukemia 19: 1106-1107; advance online publication, April 7, 2005; doi:10.1038/sj.leu.2403742
